PortfoliosLab logoPortfoliosLab logo
COGT vs. CDTX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

COGT vs. CDTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cogent Biosciences, Inc. (COGT) and Cidara Therapeutics, Inc. (CDTX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

COGT vs. CDTX - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
COGT
Cogent Biosciences, Inc.
8.36%355.38%32.65%-49.13%34.73%-23.60%289.93%-83.64%-60.40%
CDTX
Cidara Therapeutics, Inc.
0.22%721.76%69.27%4.98%-40.45%-36.50%-47.92%63.40%-41.25%

Fundamentals

Market Cap

COGT:

$2.60B

CDTX:

$3.44B

EPS

COGT:

-$3.33

CDTX:

-$11.88

PB Ratio

COGT:

4.47

CDTX:

8.15

Total Revenue (TTM)

COGT:

$0.00

CDTX:

$0.00

Gross Profit (TTM)

COGT:

$0.00

CDTX:

-$45.00M

EBITDA (TTM)

COGT:

-$333.36M

CDTX:

-$189.91M

Returns By Period


COGT

1D
8.76%
1M
-0.93%
YTD
8.36%
6M
168.04%
1Y
542.57%
3Y*
52.79%
5Y*
33.49%
10Y*

CDTX

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

COGT vs. CDTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

COGT
COGT Risk / Return Rank: 9999
Overall Rank
COGT Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
COGT Sortino Ratio Rank: 9999
Sortino Ratio Rank
COGT Omega Ratio Rank: 9898
Omega Ratio Rank
COGT Calmar Ratio Rank: 9999
Calmar Ratio Rank
COGT Martin Ratio Rank: 9999
Martin Ratio Rank

CDTX
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

COGT vs. CDTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cogent Biosciences, Inc. (COGT) and Cidara Therapeutics, Inc. (CDTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


COGTCDTXDifference

Sharpe ratio

Return per unit of total volatility

4.04

Sortino ratio

Return per unit of downside risk

6.26

Omega ratio

Gain probability vs. loss probability

1.80

Calmar ratio

Return relative to maximum drawdown

15.02

Martin ratio

Return relative to average drawdown

44.68

COGT vs. CDTX - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


COGTCDTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

4.04

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.35

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.01

Correlation

The correlation between COGT and CDTX is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

COGT vs. CDTX - Dividend Comparison

Neither COGT nor CDTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

COGT vs. CDTX - Drawdown Comparison


Loading graphics...

Drawdown Indicators


COGTCDTXDifference

Max Drawdown

Largest peak-to-trough decline

-98.09%

Max Drawdown (1Y)

Largest decline over 1 year

-30.57%

Max Drawdown (5Y)

Largest decline over 5 years

-76.34%

Current Drawdown

Current decline from peak

-42.62%

Average Drawdown

Average peak-to-trough decline

-78.48%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.06%

Volatility

COGT vs. CDTX - Volatility Comparison


Loading graphics...

Volatility by Period


COGTCDTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.39%

Volatility (6M)

Calculated over the trailing 6-month period

85.97%

Volatility (1Y)

Calculated over the trailing 1-year period

135.60%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

95.11%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

168.06%

Financials

COGT vs. CDTX - Financials Comparison

This section allows you to compare key financial metrics between Cogent Biosciences, Inc. and Cidara Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober00
(COGT) Total Revenue
(CDTX) Total Revenue
Values in USD except per share items